Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

被引：0
|
作者：
Ogdie, Alexis [1 ]
Mease, Philip [2 ,3 ]
Nantel, Francois [4 ]
Lavie, Frederic [5 ]
Sharaf, Mohamed [6 ]
Rampakakis, Emmanouil [7 ]
Marzo-Ortega, Helena [8 ,9 ]
Gossec, Laure [10 ]
机构：
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[2] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[3] Univ Washington, Sch Med, Seattle, WA USA
[4] Nantel MedSci Consult, Montreal, PQ, Canada
[5] Janssen Cilag Global Med Affairs, Immunol Global Med Affairs, Issy Les Moulineaux, France
[6] Middle East FZ LLC, Johnson & Johnson, Dubai, U Arab Emirates
[7] McGill Univ, Dept Pediat Sci Affairs, JSS Med Res Inc, Montreal, PQ, Canada
[8] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England
[9] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[10] Sorbonne Univ, Paris, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
IMPORTANT-DIFFERENCE;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0583
引用
收藏
页码：1184 / 1187
页数：4
相关论文
共 50 条
  • [1] Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
    Strand, Vibeke
    Kaeley, Gurjit
    Bergman, Martin
    Gladman, Dafna
    Coates, Laura
    Hur, Peter
    Kim, Nina
    Parikh, Bhumik
    Pertel, Patricia
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [2] Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis
    Rahman, Proton
    Boehncke, Wolf-Henning
    Mease, Philip J.
    Gottlieb, Alice B.
    McInnes, Iain B.
    Shawi, May
    Wang, Yanli
    Sheng, Shihong
    Kollmeier, Alexa P.
    Theander, Elke
    Yu, Jenny
    Leibowitz, Evan
    Marrache, A. Marilise
    Coates, Laura C.
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (06) : 769 - 780
  • [3] Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
    Coates, Laura
    Bushmakin, Andrew
    FitzGerald, Oliver
    Gladman, Dafna
    Fallon, Lara
    Cappelleri, Joseph
    Hsu, Ming-Ann
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [4] Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies
    Schneeberger, Emilce E.
    Citera, Gustavo
    Nash, Peter
    Smolen, Josef S.
    Mease, Philip J.
    Soriano, Enrique R.
    Helling, Claudia
    Szumski, Annette E.
    Mundayat, Rajiv
    de Leon, Dario Ponce
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 58
  • [5] Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
    Helliwell, Philip
    Bushmakin, Andrew
    Gladman, Dafna
    FitzGerald, Oliver
    Fallon, Lara
    Cappelleri, Joseph
    Hsu, Ming-Ann
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [6] Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
    Mease, Philip J.
    Helliwell, Philip S.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Sweet, Kristen
    Shawi, May
    Karyekar, Chetan S.
    Deodhar, Atul
    van der Heijde, Desiree
    LANCET RHEUMATOLOGY, 2021, 3 (10): : E715 - E723
  • [7] Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
    Ana-Maria Orbai
    M. Elaine Husni
    Dafna D. Gladman
    Ying Ying Leung
    Stefan Siebert
    William Tillett
    Marijn Vis
    Olivier Chambenoit
    Xiangyi Meng
    Philip J. Mease
    Rheumatology and Therapy, 2021, 8 : 1223 - 1240
  • [8] Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
    Orbai, Ana-Maria
    Husni, M. Elaine
    Gladman, Dafna D.
    Leung, Ying Ying
    Siebert, Stefan
    Tillett, William
    Vis, Marijn
    Chambenoit, Olivier
    Meng, Xiangyi
    Mease, Philip J.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (03) : 1223 - 1240
  • [9] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
    Ritchlin, Christopher T.
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Rampakakis, Emmanouil
    Chakravarty, Soumya
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [10] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
    Felten, Renaud
    Widawski, Laura
    Spielman, Lionel
    Gottenberg, Jacques-Eric
    Duret, Pierre-Marie
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Constantin, Caren
    Campana, Vincenza
    Messer, Laurent
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
12345